Dermatology consultation may decrease telaprevir discontinuation among patients with severe triple therapy-associated rash
Publication
, Conference
Strazzula, L; Pratt, D; Zardas, J; Kroshinsky, D
Published in: JOURNAL OF INVESTIGATIVE DERMATOLOGY
2013
Duke Scholars
Published In
JOURNAL OF INVESTIGATIVE DERMATOLOGY
ISSN
0022-202X
Publication Date
2013
Volume
133
Start / End Page
S189 / S189
Related Subject Headings
- Dermatology & Venereal Diseases
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Strazzula, L., Pratt, D., Zardas, J., & Kroshinsky, D. (2013). Dermatology consultation may decrease telaprevir discontinuation among patients with severe triple therapy-associated rash. In JOURNAL OF INVESTIGATIVE DERMATOLOGY (Vol. 133, pp. S189–S189).
Strazzula, L., D. Pratt, J. Zardas, and D. Kroshinsky. “Dermatology consultation may decrease telaprevir discontinuation among patients with severe triple therapy-associated rash.” In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 133:S189–S189, 2013.
Strazzula L, Pratt D, Zardas J, Kroshinsky D. Dermatology consultation may decrease telaprevir discontinuation among patients with severe triple therapy-associated rash. In: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2013. p. S189–S189.
Strazzula, L., et al. “Dermatology consultation may decrease telaprevir discontinuation among patients with severe triple therapy-associated rash.” JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 133, 2013, pp. S189–S189.
Strazzula L, Pratt D, Zardas J, Kroshinsky D. Dermatology consultation may decrease telaprevir discontinuation among patients with severe triple therapy-associated rash. JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2013. p. S189–S189.
Published In
JOURNAL OF INVESTIGATIVE DERMATOLOGY
ISSN
0022-202X
Publication Date
2013
Volume
133
Start / End Page
S189 / S189
Related Subject Headings
- Dermatology & Venereal Diseases
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences